NO20024741L - 8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer - Google Patents
8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorerInfo
- Publication number
- NO20024741L NO20024741L NO20024741A NO20024741A NO20024741L NO 20024741 L NO20024741 L NO 20024741L NO 20024741 A NO20024741 A NO 20024741A NO 20024741 A NO20024741 A NO 20024741A NO 20024741 L NO20024741 L NO 20024741L
- Authority
- NO
- Norway
- Prior art keywords
- alkoxy
- hydroxy
- hydrogen
- optionally substituted
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Forbindelse med formelen. i fri eller saltform, hvor Rer hydrogen eller alkyl eventuelt substituert med hydroksy, alkoksy eller alkyltio, Rer hydrogen, alkyl, hydroksyalkyl, alkylkarbonyloksyalkyl, alkoksyalkyl, alkyltioalkyl, alkenyl, cykloalkylalkyl, heterocyklylalkyl, aralkyl hvori arylringen derav eventuelt er sammensmeltet til en 5-leddet heterocyklisk gruppe eller eventuelt er substituert med en eller flere substituenter utvalgt fra alkoksy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroksy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino eller dialkylaminosulfonylamino,. Rer hydrogen eller alkyl eventuelt substituert med hydroksy, alkoksy eller alkyltio,. Rer hydrogen eller alkyl, Rer en quinolinyl, isoquinolinyl eller. oksodihydroisoquinolinylgruppe eventuelt sammensmeltet til en 5-leddet heterocyklisk gruppe og eventuelt substituert med en eller flere substituenter utvalgt fra halogen, cyano, hydroksy, alkyl, hydroksyalkyl, alkoksyalkyl, alkyltioalkyl, alkoksy, alkyltio, alkenyl, alkoksykarbonyl, alkynyl, karboksyl, acyl, en gruppe med formel N(R)R, aryl eventuelt substituert med en eller flere substituenter uvalgt fra halogen eller alkoksy, eller heteroaryl som har 5 eller 6 ringatomer bundet gjennom et ringatom til det indikerte karbonatomet, og Rog Rer hver uavhengig hydrogen eller alkyl, eventuelt substituert med hydroksy eller alkoksy eller en av Rog R7 er hydrogen og den andre er acyl, eller Rog Rsammen med nitrogenatomet til hvilket de er bundet betegner en 5- eller 6-leddet heterocyklylgruppe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008694.2A GB0008694D0 (en) | 2000-04-07 | 2000-04-07 | Organic compounds |
| PCT/EP2001/003909 WO2001077110A1 (en) | 2000-04-07 | 2001-04-05 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20024741D0 NO20024741D0 (no) | 2002-10-02 |
| NO20024741L true NO20024741L (no) | 2002-10-02 |
Family
ID=9889516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024741A NO20024741L (no) | 2000-04-07 | 2002-10-02 | 8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030171384A1 (no) |
| EP (1) | EP1268480B1 (no) |
| JP (1) | JP3869725B2 (no) |
| KR (1) | KR100526094B1 (no) |
| CN (1) | CN1176922C (no) |
| AR (1) | AR028531A1 (no) |
| AT (1) | ATE253576T1 (no) |
| AU (2) | AU2001273921B2 (no) |
| BR (1) | BR0109855A (no) |
| CA (1) | CA2403514C (no) |
| CZ (1) | CZ20023305A3 (no) |
| DE (1) | DE60101158T2 (no) |
| DK (1) | DK1268480T3 (no) |
| ES (1) | ES2210169T3 (no) |
| GB (1) | GB0008694D0 (no) |
| HU (1) | HUP0300565A3 (no) |
| IL (1) | IL152078A0 (no) |
| MX (1) | MXPA02009903A (no) |
| MY (1) | MY119238A (no) |
| NO (1) | NO20024741L (no) |
| NZ (1) | NZ521361A (no) |
| PE (1) | PE20020228A1 (no) |
| PL (1) | PL212407B1 (no) |
| PT (1) | PT1268480E (no) |
| RU (1) | RU2269529C2 (no) |
| SK (1) | SK14282002A3 (no) |
| TR (1) | TR200400185T4 (no) |
| WO (1) | WO2001077110A1 (no) |
| ZA (1) | ZA200207956B (no) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| BR0311760A (pt) * | 2002-06-12 | 2005-03-29 | Hoffmann La Roche | Composto, pró-droga de um composto, processo para a preparação do composto, composições farmacêuticas que compreendem o mesmo, sua utilização e método de tratamento de diabetes do tipo 2 |
| SI1532149T1 (sl) * | 2002-08-21 | 2010-05-31 | Boehringer Ingelheim Pharma | amino piperidin il ksantini njihova priprava in njihova uporaba kot zdravila |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| AU2004213124A1 (en) * | 2003-02-19 | 2004-09-02 | F. Hoffmann-La Roche Ag | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors |
| US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1636229A4 (en) * | 2003-06-06 | 2008-07-30 | Endacea Inc | ADENOSINE A1 RECEPTOR ANTAGONISTS |
| KR100658080B1 (ko) * | 2003-08-26 | 2006-12-15 | 비오이 하이디스 테크놀로지 주식회사 | 백라이트 조립용 지그 |
| TW200605893A (en) * | 2004-02-12 | 2006-02-16 | Novartis Ag | Use of organic compounds |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CN1980895A (zh) * | 2004-05-08 | 2007-06-13 | 神经能质公司 | 1－芳基－4－取代的异喹啉 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| WO2008151734A1 (en) * | 2007-06-13 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of hearing impairment |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| AU2010228902A1 (en) * | 2009-03-26 | 2011-10-06 | Mapi Pharma Limited | Process for the preparation of alogliptin |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| KR20190050871A (ko) | 2010-06-24 | 2019-05-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AU2012219316A1 (en) * | 2011-02-18 | 2013-10-03 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| KR101985384B1 (ko) | 2011-07-15 | 2019-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014071044A1 (en) * | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558162B1 (fr) * | 1984-01-17 | 1986-04-25 | Adir | Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| AU4501199A (en) * | 1998-06-03 | 1999-12-20 | Almirall Prodesfarma S.A. | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors |
| GB9828340D0 (en) * | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
-
2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
-
2001
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 CA CA002403514A patent/CA2403514C/en not_active Expired - Fee Related
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 EP EP01940294A patent/EP1268480B1/en not_active Expired - Lifetime
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/en active IP Right Grant
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active IP Right Cessation
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
-
2002
- 2002-10-02 NO NO20024741A patent/NO20024741L/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20024741L (no) | 8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer | |
| RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| HUP9901016A2 (hu) | 4-Kinolinkarboxamid-származékok, előállításuk, valamint neurokinin-3 (NK-3) és neurokinin-2 (NK-2) receptor antagonistákként történő felhasználásuk | |
| HUP0400828A2 (hu) | Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302337A2 (hu) | Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| TR200003598T2 (tr) | Amid türevleri ve nosiseptin antagonistleri | |
| CO5261607A1 (es) | Nuevo uso | |
| EA199900866A1 (ru) | Пиразолопиримидиноны, которые ингибируют циклический гуанозин-3',5'-монофосфат-фосфодиэстеразу типа 5 (cgmp pde5), для лечения сексуального расстройства | |
| AR018452A1 (es) | Compuestos antibioticos de oxazolidinona sustituida, proceso para su preparacion, metodo para producir un efecto antibacteriano, composicionesfarmaceuticas que los contienen y su uso para preparar medicamentos | |
| HRP20040429B1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
| AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
| HUP9902459A2 (hu) | Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására | |
| HUP9702356A2 (hu) | Glikogén foszforiláz inhibitor hatású 1H-indol-2-karbonsav-származékok alkalmazása gyógyászati készítmények előállítására | |
| CA1272482C (en) | QUINOLINECARBOXYLIC ACID DERIVATIVES | |
| DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
| SE0201937D0 (sv) | Therapeutic agents | |
| RU94034117A (ru) | Производные азола, способы их получения и антигрибковое средство | |
| DK0759027T3 (da) | Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase | |
| KR910007883A (ko) | 퀴놀린 유도체, 그의 제조방법 및 용도 | |
| NO812355L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater | |
| HUP0101469A2 (hu) | 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként | |
| ATE259359T1 (de) | Benzoxazol-derivate zur verwendung als integrin- inhibitoren | |
| HUP9902316A2 (hu) | Endotelin-antagonista hatású 4-(benzo-1,3-dioxolil)-pirrolidin-3-karbonsav-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| NZ335975A (en) | Heterocyclic substituted pyrrolidine amide derivatives useful in treating respiratory diseases | |
| BG106079A (en) | Cyclocarbamate derivatives as progesterone receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |